TriSalus Life Sciences (NASDAQ:TLSI) Stock Price Up 2% – Should You Buy?

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) was up 2% during trading on Wednesday . The company traded as high as $4.50 and last traded at $4.49. Approximately 163,177 shares traded hands during trading, a decline of 8% from the average daily volume of 177,035 shares. The stock had previously closed at $4.40.

Analysts Set New Price Targets

A number of equities research analysts recently commented on TLSI shares. Zacks Research upgraded TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. Weiss Ratings restated a “sell (d-)” rating on shares of TriSalus Life Sciences in a research report on Friday, April 10th. Canaccord Genuity Group decreased their price target on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Finally, Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $7.00.

TriSalus Life Sciences Trading Up 2.0%

The firm has a fifty day simple moving average of $4.45 and a 200-day simple moving average of $5.20. The stock has a market cap of $275.26 million, a price-to-earnings ratio of -2.45 and a beta of 0.54.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01. The firm had revenue of $13.21 million for the quarter, compared to analyst estimates of $13.20 million. On average, equities analysts predict that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current fiscal year.

Insider Transactions at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela sold 15,944 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $3.85, for a total transaction of $61,384.40. Following the transaction, the chief executive officer owned 752,987 shares of the company’s stock, valued at approximately $2,898,999.95. This represents a 2.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders sold 30,150 shares of company stock worth $119,849. 16.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TLSI. Goldman Sachs Group Inc. acquired a new position in TriSalus Life Sciences during the 1st quarter worth $187,000. Geode Capital Management LLC lifted its holdings in TriSalus Life Sciences by 107.4% during the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after buying an additional 235,627 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after buying an additional 7,519 shares in the last quarter. New York State Common Retirement Fund acquired a new position in shares of TriSalus Life Sciences in the 2nd quarter valued at $108,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of TriSalus Life Sciences in the 2nd quarter valued at $47,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.